Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $0.1436 (1.84%) ($0.1436 - $0.1436) on Fri. May. 6, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.89% (three month average) | RSI | 28 | Latest Price | $0.1436(1.84%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TNXP declines -7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) ARKK(98%) IBB(97%) IYT(96%) INDA(95%) VT(95%) | Factors Impacting TNXP price | TNXP will decline at least -3.445% in a week (0% probabilities). SHY(-32%) UUP(-16%) BND(-14%) BNDX(-27%) IGOV(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.445% (StdDev 6.89%) | Hourly BBV | -2.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $0.16 | 5 Day Moving Average | $0.15(-4.27%) | 10 Day Moving Average | $0.15(-4.27%) | 20 Day Moving Average | $0.16(-10.25%) | To recent high | -44.4% | To recent low | 1.8% | Market Cap | $38m | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |